



REVIEW ARTICLE

Recent Trends of Fast Dissolving Tablet - An Overview of Formulation Technology

A Gupta^{1*}, AK Mishra¹, V Gupta¹, P Bansal², R Singh³, AK Singh⁴

¹ National Institute of Ayurvedic Pharmaceutical Research, Patiala, India.

² Baba Farid University of Health Sciences, Faridkot, India.

³ School of Pharmaceutical Sciences, Shobhit University, Meerut, India.

⁴ National Botanical Research Institute, Rana Pratap Marg, Lucknow, India.

ABSTRACT

In recent decades, a variety of pharmaceutical research has been conducted to develop new dosage forms. Among the dosage forms developed to facilitate ease of medication, the rapid disintegrating tablet (RDT) is one of the most widely employed commercial products. As our society is becoming increasingly aged, the development of Fast- or mouth dissolving tablets have been formulated for pediatric, geriatric, and bedridden patients and for active patients who are busy and traveling and may not have access to water. Such formulations provide an opportunity for product line extension in the many elderly persons will have difficulties in taking conventional oral dosage forms (viz., solutions, suspensions, tablets, and capsules) because of hand tremors and dysphagia. Swallowing problems also are common in young individuals because of their underdeveloped muscular and nervous systems. Other groups that may experience problems using conventional oral dosage forms include the mentally ill, the developmentally disabled, and patients who are uncooperative, on reduced liquid-intake plans, or are nauseated. In some cases such as motion sickness, sudden episodes of allergic attack or coughing, and an unavailability of water, swallowing conventional tablets may be difficult. This paper summarizes the formulation methods and drug formulation coming in market.

Key Words: Mouth dissolving, Lyophilization, Direct compression, Fast dissolving tablet.

INTRODUCTION

Recent developments in the technology have presented viable dosage alternatives from oral route for pediatric, geriatric, bedridden, nauseous or noncompliant patients. Buccal

drug delivery has lately become an important route of drug administration. Various bioadhesive mucosal dosage forms have been developed, which includes adhesive tablets, gels, ointments, patches and more recently the use of polymeric films for buccal delivery, also known as mouth dissolving films^[1]. A fast-dissolving drug delivery system, in most cases, is a tablet that dissolves or disintegrates in the oral cavity without the need of water

*Corresponding Author: Abhishek Gupta

Email: abhibbd2006@gmail.com,

akhileshmishra2010@gmail.com

Contact No: 09023468460, 09023467630

or chewing. Most fast-dissolving delivery system films must include substances to mask the taste of the active ingredient. This masked active ingredient is then swallowed by the patient's saliva along with the soluble and insoluble excipients.²⁻³. These are also called melt-in-mouth tablets, repimelts, porous tablets, oro-dispersible, quick dissolving or rapid disintegrating tablets, Mouth dissolving tablets, fast dissolving, rapid –dissolve, fast melts, Effervescent Drug Absorption system, Orosolv, Zydis etc. Mouth dissolving films, a new drug delivery system for the oral delivery of the drugs, was developed based on the technology of the transdermal patch. The delivery system consists of a very thin oral strip, which is simply placed on the patient's tongue or any oral mucosal tissue, instantly wet by saliva the film rapidly hydrates and adheres onto the site of application. It then rapidly disintegrates and dissolves to release the medication for oromucosal absorption or with formula modifications, will maintain the quick-dissolving aspects allow for gastrointestinal absorption to be achieved when swallowed. In contrast to other existing, rapid dissolving dosage forms, which consist of liophylisates, the rapid films can be produced with a manufacturing process that is competitive with the manufacturing costs of conventional tablets^[4]. These are novel types; of tablets that disintegrate/dissolve/ disperse in saliva within few seconds. According to European Pharmacopoeia, the ODT should disperse/disintegrate in less than three minutes. The basic approach used in development of MDT is the use of superdisintegrants like Cross linked carboxymethyl cellulose (Croscarmellose), Sodium starch glycolate (Primogel, Explotab). Polyvinylpyrrolidone (Polyplasdone) etc. which provide instantaneous disintegration of tablet after putting on tongue, thereby releasing the drug in saliva. The bioavailability of some drugs may be increased due to absorption of drugs in oral cavity and also due to pregastric absorption of saliva containing dispersed drugs that pass down into the stomach. Moreover, the amount of drug that is subject to first pass metabolism is reduced as compared to standard tablets^[5-8]. Another approach used in developing MD tablets is maximizing pore structure of the tablets.

Different types of technologies have been employed for the formulation of mouth dissolving tablets viz freeze-drying, Tablet Molding, Direct Compression Method, spray drying and sublimation Technology etc. have been tried by researchers to maximize the pore structure of tablet matrix^[9-13].

Requirements of Fast Dissolving Tablets an ideal FDT should^[14]

1. Require no water for oral administration, yet dissolve / disperse/ disintegrate in mouth in a matter of seconds.
2. Have a pleasing mouth feel.
3. Have an acceptable taste masking property.
4. Be harder and less friable
5. Leave minimal or no residue in mouth after administration
6. Exhibit low sensitivity to environmental conditions (temperature and humidity).
7. Allow the manufacture of tablet using conventional processing and packaging equipments.

Advantages of Fast Dissolving Tablets^[15]

1. Ease of administration to patients who cannot swallow, such as the elderly, stroke victims and bedridden patients; patients who should not swallow, such as renal failure patients; and who refuse to swallow, such as paediatrics, geriatric and psychiatric patients^[16-17].
2. Patient's compliance for disabled bedridden patients and for travelling and busy people, who do not have ready access to water.
3. Good mouth feel property of MDDDS helps to change the basic view of medication as "bitter pill", particularly for paediatric patients due to improved taste of bitter drugs.
4. Convenience of administration and accurate dosing as compared to liquid Formulations.
5. Benefit of liquid medication in the form of solid preparation.
6. More rapid drug absorption from the pre-gastric area i.e. mouth, pharynx and oesophagus which may produce rapid onset of action^[17-18].
7. Pre-gastric absorption can result in improved bioavailability, reduced dose and improved clinical performance by reducing side effects^[19].

8. New business opportunities: product differentiation, line extension and life-cycle management, exclusivity of product promotion and patent-life extension [17-18].

METHODOLOGY EMPLOYED FOR FAST DISSOLVING FORMULATIONS

1. Melt granulation

Melt granulation technique is a process by which pharmaceutical powders are efficiently agglomerated by a meltable binder. The advantage of this technique compared to a conventional granulation is that no water or organic solvents is needed. Because there is no drying step, the process is less time consuming and uses less energy than wet granulation. It is a useful technique to enhance the dissolution rate of poorly water-soluble drugs, such as griseofulvin [20]. This approach to prepare FDT with sufficient mechanical integrity, involves the use of a hydrophilic waxy binder (Superpolystate[®], PEG – 6 – stearate). Superpolystate[®] is a waxy material with a melting point of 33–37°C and a HLB value of 9. So it will not only act as a binder and increase the physical resistance of tablets but will also help the disintegration of the tablets as it melts in the mouth and solubilises rapidly leaving no residues [21].

2. Phase transition process

It is concluded that a combination of low and high melting point sugar alcohols, as well as a phase transition in the manufacturing process, are important for making FDTs without any special apparatus. FDT were produced by compressing powder containing erythritol (melting point: 122 °C) and xylitol (melting point: 93 95 °C), and then heating at about 93 °C for 15 min. After heating, the median pore size of the tablets was increased and tablet hardness was also increased. The increase of tablet hardness with heating and storage did not depend on the crystal state of the lower melting point sugar alcohol [22].

3. Sublimation

In this method a subliming material like camphor, is removed by sublimation from compressed tablets and high porosity is achieved due to the formation of many pores

where camphor particles previously existed in the compressed tablets prior to sublimation of the camphor. A high porosity was achieved due to the formation of many pores where camphor particles previously existed in the compressed mannitol tablets prior to sublimation of the camphor. These compressed tablets which have high porosity (approximately 30%) rapidly dissolved within 15 seconds in saliva [23]. Granules containing nimusulide, camphor, crospovidone, and lactose were prepared by wet granulation technique. Camphor was sublimed from the dried granules by vacuum exposure [24]. Conventional methods like dry granulation, wet granulation and direct compression with highly soluble excipients, super disintegrants and/or effervescent systems can also be used.

4. Three-dimensional Printing (3DP)

Three-dimensional printing (3DP) is a rapid prototyping (RP) technology. Prototyping involves constructing specific layers that uses powder processing and liquid binding materials. A novel fast dissolving drug delivery device (DDD) with loose powders in it was fabricated using the three dimensional printing (3DP) process. Based on computer-aided design models, the DDD containing the drug acetaminophen were prepared automatically by 3DP system [25]. It was found that rapidly disintegrating oral tablets with proper hardness can be prepared using TAG. The rapid disintegration of the TAG tablets seemed due to the rapid water penetration into the tablet resulting from the large pore size and large overall pore volume [26].

5. Mass Extrusion

This technology involves softening of the active blend using the solvent mixture of water soluble polyethylene glycol and methanol and expulsion of softened mass through the extruder or syringe to get a cylindrical shaped extrude which are finally cut into even segments using heated blade to form tablets. This process can also be used to coat granules of bitter drugs to mask their taste [15, 27].

6. Spray Drying

In this technique, gelatin can be used as a supporting agent and as a matrix, mannitol as a bulking agent and sodium starch glycolate or

crosscarmellose or croscopovidone are used as superdisintegrants. Tablets manufactured from the spray-dried powder have been reported to disintegrate in less than 20 seconds in aqueous medium. The formulation contained bulking agent like mannitol and lactose, a superdisintegrant like sodium starch glycolate & croscarmellose sodium and acidic ingredient (citric acid) and/or alkaline ingredients (e.g. sodium bicarbonate). This spray-dried powder, which compressed into tablets showed rapid disintegration and enhanced dissolution. Maximum drug release and minimum disintegration time were observed with Kollidon CL excipient base as compared to tablets prepared by direct compression, showing the superiority of the spray dried excipient base technique over direct compression technique [28].

7. Cotton Candy Process

The FLASHDOSE® is a MDDDS manufactured using Shearform™ technology in association with Ceform TI™ technology to eliminate the bitter taste of the medicament [29-30]. The Shearform technology is employed in the preparation of a matrix known as 'floss', made from a combination of excipients, either alone or with drugs. The floss is a fibrous material similar to cotton-candy fibers, commonly made of saccharides such as sucrose, dextrose, lactose and fructose at temperatures ranging between 180–266 °F [31]. However, other polysaccharides such as polymaltodextrins and polydextrose can be transformed into fibers at 30–40% lower temperature than sucrose. This modification permits the safe incorporation of thermolabile drugs into the formulation [32]. The tablets manufactured by this process are highly porous in nature and offer very pleasant mouthfeel due to fast solubilization of sugars in presence of saliva. The manufacturing process can be divided into four steps as detailed below.

a) Floss Blend

In this step, 80% sucrose in combination with mannitol/dextrose and 1% surfactant is blended to form the floss mix. The surfactant acts as a crystallization enhancer in maintaining the structural integrity of the floss fibers. It also helps in the conversion of amorphous sugar into crystalline form from an outer portion of

amorphous sugar mass and subsequently converting the remaining portion of the mass to complete crystalline structure. This process helps to retain the dispersed drug in the matrix, thereby minimizing migration out of the mixture [33].

b) Floss Processing

The floss formation machine uses flash heat and flash flow processes to produce matrix from the carrier material. The machine is similar to that used in 'cotton-candy' formation which consists of a spinning head and heating elements. In the flash heat process, the heat induces an internal flow condition of the carrier material. This is followed by its exit through the spinning head (2000–3600 rpm) that flings the floss under centrifugal force and draws into long and thin floss fibers, which are usually amorphous in nature [34-36].

c) Floss Chopping and Conditioning

This step involves the conversion of fibers into smaller particles in a high shear mixer granulator. The conditioning is performed by partial crystallization through an ethanol treatment (1%) which is sprayed onto the floss and subsequently evaporated to impart improved flow and cohesive properties to the floss [31].

d) Blending and Compression

Finally, the chopped and conditioned floss fibers are blended with the drug alongwith other required excipients and compressed into tablets. In order to improve the mechanical strength of the tablets, a curing step is also carried out which involves the exposure of the dosage forms to elevated temperature and humidity conditions, (40 °C and 85% RH for 15 min). This is expected to cause crystallization of the floss material that results in binding and bridging to improve the structural strength of the dosage form [37].

8. Tablet Molding

Molding process is of two type's i.e. solvent method and heat method. Solvent method involves moistening the powder blend with a hydro alcoholic solvent followed by compression at low pressures in molded plates to form a wetted mass (compression molding). The solvent is then removed by air-drying. The tablets manufactured in this manner are less compact than compressed tablets and possess a

porous structure that hastens dissolution. The heat molding process involves preparation of a suspension that contains a drug, agar and sugar (e.g. mannitol or lactose) and pouring the suspension in the blister packaging wells, solidifying the agar at the room temperature to form a jelly and drying at 30°C under vacuum. The mechanical strength of molded tablets is a matter of great concern. Binding agents, which increase the mechanical strength of the tablets, need to be incorporated. Taste masking is an added problem to this technology. The taste masked drug particles were prepared by spray congealing a molten mixture of hydrogenated cottonseed oil, sodium carbonate, lecithin, polyethylene glycol and an active ingredient into a lactose based tablet triturate form. Compared to the lyophilization technique, tablets produced by the molding technique are easier to scale up for industrial manufacture^[38].

9. Lyophilization or Freeze-Drying

Freeze drying is the process in which water is sublimed from the product after it is frozen. This technique creates an amorphous porous structure that can dissolve rapidly. A typical procedure involved in the manufacturing of ODT using this technique is mentioned here. The active drug is dissolved or dispersed in an aqueous solution of a carrier/polymer. The mixture is done by weight and poured in the walls of the preformed blister packs. The trays holding the blister packs are passed through liquid nitrogen freezing tunnel to freeze the drug solution or dispersion. Then the frozen blister packs are placed in refrigerated cabinets to continue the freeze-drying. After freeze-drying the aluminum foil backing is applied on a blister-sealing machine. Finally the blisters are packaged and shipped. The freeze-drying technique has demonstrated improved absorption and increase in bioavailability. The major disadvantages of lyophilization technique are that it is expensive and time consuming; fragility makes conventional packaging unsuitable for these products and poor stability under stressed conditions^[38].

10. Direct Compression^[38]

Direct compression represents the simplest and most cost effective tablet manufacturing technique. This technique can now be applied to

preparation of ODT because of the availability of improved excipients especially superdisintegrants and sugar based excipients.

a) Superdisintegrants:

In many orally disintegrating tablet technologies based on direct compression, the addition of superdisintegrants principally affects the rate of disintegration and hence the dissolution. The presence of other formulation ingredients such as water-soluble excipients and effervescent agents further hastens the process of disintegration. For the success of fast dissolving tablet, the tablet having quick dissolving property which is achieved by using the super disintegrants, Some important examples of super disintegrants are given in **Table 1** with their mechanism of action.

b) Sugar Based Excipients:

This is another approach to manufacture ODT by direct compression. The use of sugar based excipients especially bulking agents like dextrose, fructose, isomalt, lactitol, maltitol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose and xylitol, which display high aqueous solubility and sweetness, and hence impart taste masking property and a pleasing mouthfeel. Mizumoto et al have classified sugar-based excipients into two types on the basis of molding and dissolution rate.

11. Nanonization

A recently developed Nanomelt technology involves reduction in the particle size of drug to nanosize by milling the drug using a proprietary wet-milling technique³⁹. The nanocrystals of the drug are stabilized against agglomeration by surface adsorption on selected stabilizers, which are then incorporated into MDTs. This technique is especially advantageous for poor water soluble drugs. Other advantages of this technology include fast disintegration/dissolution of nanoparticles leading to increased absorption and hence higher bioavailability and reduction in dose, cost effective manufacturing process, conventional packaging due to exceptional durability and wide range of doses (up to 200 mg of drug per unit)^[15].

Table 1: List of Super Disintegrants

Superdisintegrants	Example	Mechanism Of action	Special comment
Crosscarmellose® Ac-Di-Sol® Nymce ZSX® Primellose®Solutab® Vivasol®L-HPC	Crosslinked cellulose	-Swells 4-8 folds in < 10 seconds. -Swelling and wicking both.	-Swells in two dimensions. -Direct compression or granulation -Starch free
Crosspovidone Crosspovidon M® Kollidon® Polyplasdone®	Crosslinked PVP	-Swells very little and returns to original size after compression but act by capillary action	-Water insoluble and spongy in nature so get porous tablet
Sodium starch glycolate Explotab® Primogel® Alginic acid NF Satialgine®	Crosslinked starch Crosslinked alginic acid	-Swells 7-12 folds in < 30 seconds -Rapid swelling in aqueous medium or wicking action	-Swells in three dimensions and high level serve as sustain release matrix -Promote disintegration in both dry or wet granulation
Soy polysaccharides Emcosoy®	Natural super disintegrant	-Does not contain any starch or sugar. Used in nutritional products	-
Calcium silicate		-Wicking action	Highly porous, Optimum concentration is between 20-40%

Important marketed preparation of fast dissolving films and fast dissolving tablets

There are number of important marketed preparation of fast dissolving films and fast

dissolving tablets are listed in **table 2** and **table 3** respectively.

Table 2: List of Marketed Fast Dissolving Films ^[40-46]

S. No.	Product	Manufactured By
1.	Dextromethorphan HBr (cough suppressant), Diphenhydramine Citrate (cough and cold), Breath Strips	MonoSolRx
2.	Donepezil rapid dissolving films, Ondansatrom rapid dissolving films	Labtec Pharma
3.	Life-saving rotavirus vaccine to infants Johns	Hopkins undergraduate biomedical engineering students
4.	Methylcobalamin fast dissolving films, Diphenhydramine HCl fast dissolving films, Dextromethorphan fast dissolving films, Folic Acid 1mg fast dissolving films, Caffeine fast dissolving films	Hughes medical corporation
5.	Altoid cinnamon strips, Boots vitamin c strips, Cool shock peppermint strips, Benzocaine films, Caffeine films	Dow chemical company
6.	Listerine Pocket Paks Breath Freshening Strips	Pfizer's Warner-Lambert consumer

- | | | |
|----|---|-----------------------|
| 7. | Energy strips - Caffeine 20mg, Acetyl Salicylic Acid (ASA), Ondansetron HCl, Dexamethasone, Nitroglycerine, Risperidone Vitamin B12, melatonin, folic acid, biotin Benzocaine, Diphenhydramine HCl, Dextrometorphan | ODF Technologies Inc. |
|----|---|-----------------------|

Table 3: List Of Marketed Fast Dissolving Tablets ^[47-48]

S. No.	Trade Name	Active Drug	Manufacturer
1.	Felden fast melt	Piroxicam	Pfiser Inc., NY, USA
2.	Claritin redi Tab	Loratidine	Schering plough Corp., USA
3.	Maxalt MLT	Rizatriptan	Merck and Co., NJ, USA
4.	Zyprexa	Olanzapine	Eli Lilly, Indianapolis, USA
5.	Pepcid RPD	Famotidine	Merck and Co., NJ, USA
6.	Zofran ODT	Ondansetron	Glaxo Wellcome, Middlesex, UK
7.	Zoming-ZMT	Zolmitriptan	AstraZeneca, Wilmington, USA
8.	Zeplar TM	Selegiline	Amarin Corp., London, UK
9.	Tempra Quiclets	Acetaminophen	Bristol Myers Squibb, NY, USA
10.	Febrectol	Paracetamol	Prographarm, Chateaufneuf, France
11.	Nimulid MDT	Nimesulide	Panacea Biotech, New delhi , India
12.	Torrox MT	Rofecoxib	Torrent pharmaceuticals , India
13.	Olanex instab	Olanzapine	Ranbaxy lab. Ltd. New-delhi, India
14.	Romilast	Montelukast	Ranbaxy lab. Ltd. New-delhi, India
15.	Benadryl Fastmelt	Diphenhydramine and pseudoephedrine	Warner Lambert, NY, USA
16.	Propulsid Quicksolv	Cisapride monohydrate	Janssen pharmaceuticals
17.	Risperdal MTab	Risperidone	Janssen pharmaceuticals
18.	Spasfon Lyoc)	Phloroglucinol Hydrate	Farmalyoc
19.	Nurofen FlashTab)	Ibuprofen	Ethypharm
20.	Tempra Quicklets	Paracetamol	Cima Labs, Inc.
21.	Zolmig Repimelt	Zolmitriptan	Cima Labs, Inc.
22.	(NuLev	Hyoscyamine Sulfate	Cima Labs, Inc.
23.	Gaster D)	Famotidine	Yamanouchi Pharma Tech. Inc.
24.	Cibalgina DueFast	Ibuprofen	Eurand International
25.	Relivia Flash dose	Tramadol HCl	Fuisz Technology, Ltd.
26.	Hyoscyamine Sulfate ODT	Hyoscyamine Sulfate	KV Pharm.Co., Inc.
27.	Abilify Discmelt	Aripiprazole	Otsuka America/Bristol-Myers Squibb
28.	Allegra ODT	Fexofenadine	Sanofi Aventis
29.	Aricept ODT	Donepezil	Eisai Co.
30.	Clarinx RediTabs	Desloratadine	Schering-Plough
31.	Alavert Quick Dissolving Tablets	Loratadine	Wyeth
32.	Clonazepam ODT	Clonazepam	Par Pharmaceutical
33.	FazaClo	Clozapine	AzurPharma
34.	Jr. Tylenol Meltaways	Acetaminophen	McNeil Consumer Healthcare
35.	Klonopin Wafers ^[26]	Clonazepam	Roche

36. Loratadine Redidose	Loratadine	Ranbaxy
37. Mirtazapine ODT	Mirtazapine	Teva Pharmaceuticals
38. Niravam	Alprazolam	Schwarz Pharma
39. Ondansetron ODT	Ondansetron	Teva Pharmaceuticals
40. Orapred ODT	Prednisolone	Sciele Pharma
41. Parcopa	Carbidopa/levodopa	Schwarz Pharma
42. Prevacid SoluTab	Lansoprazole	Takeda Pharmaceuticals
43. Remeron SolTab	Mirtazapine	Schering-Plough
44. Risperdal M-Tab	Risperidone	Janssen
45. UNISOM SleepMelts	Diphenhydramine	Chattem
46. Zomig-ZMT	Zolmitriptan	AstraZeneca
47. Zyprexa Zydis	Olanzapine	Eli Lilly and Company
48. Citalopram ODT	Citalopram	Biovail
49. Metoclopramide Zydis	Metoclopramide	Salix Pharmaceuticals
50. Reglan ODT	Metoclopramide	Schwarz Pharma ^l
51. Tramadol/Acetaminophen ODT	Tramadol/Acetaminophen	Biovail
52. Zolpidem ODT	Zolpidem	Biovail

CONCLUSION

The development of a fast-dissolving tablet also provides an opportunity for a line extension in the marketplace; a wide range of drugs (e.g., neuroleptics, cardiovascular drugs, analgesics, antihistamines, and drugs for erectile dysfunction) can be considered candidates for this dosage form. Pharmaceutical marketing is another reason for the increase in available fast dissolving/ disintegrating products. As a drug entity nears the end of its patent life, it is common for pharmaceutical manufacturers to develop a given drug entity in a new and improved dosage form. A new dosage form allows a manufacturer to extend market exclusivity, while offering its patient population a more convenient dosage form or dosing regimen. In this regard, fast dissolving/ disintegrating tablet formulations are similar to many sustained release formulations that are now commonly available. An extension of market exclusivity, which can be provided by a fast-dissolving/disintegrating dosage form, leads to increased revenue, while also targeting underserved and under-treated patient populations. Although the cost to manufacture these specialized dosage forms exceeds that of traditional tablets, this additional cost is not being passed on to the consumer.

REFERENCE

1. Malke M, Shidhaye S, Kadam VJ. Formulation and evaluation of Oxacarbazine fast dissolve tablets. *Ind J Pharm Sci.* 2007; 69: 211-14.
2. Kuchekar BS, Atul BC, Mahajan HS. Mouth dissolving tablets: A novel drug delivery system. *Pharma Times* 2003; 35: 7-9.
3. Allen LV, Wang B. Particulate support matrix for making a rapidly dissolving tablet. *US Patent 5595761*; 1997.
4. Vollmer U, Galfetti P. Rapid film: Oral thin films as an innovative drug delivery System and dosage form. *Drug Dev Report* 2006; 64-67.
5. Sharma S. New Generation of Tablet: Fast Dissolving Tablet. available at pharmainfo.net
6. Habib W, Khankari R, Hontz J. Fast-dissolving drug delivery systems, critical review in therapeutics. *Drug Carrier Systems* 2000; 17(1): 61-72.
7. Chang R, Guo X, Burnside BA, Couch R. Fast-dissolving tablets. *Pharm. Tech.* 2000; 24(6): 52-58.
8. Dobbetti L. Fast-Melting Tablets: Developments and Technologies. *Pharm. Tech.* 2001; 44-50.
9. Gohel M, Patel M, Amin A, Agrawal R, Dave R, Bariya N. Formulation Design and Optimization of Mouth Dissolve Tablets of Nimesulide Using Vacuum Drying Technique. *AAPS Pharm SciTech* 2004; 5 (3): 63-70.
10. Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets

- by lyophilization using hydrochlorthiazide as a model drug. *Int J Pharm.* 1997; 152: 215-225.
11. Remon JP, Corveleyn S. Freeze-dried rapidly disintegrating tablets. US patent 6010719; 2000.
 12. Knistch A, Hagen E, Munz HD. Production of porous tablets. US patent 4134843; 1979.
 13. Roser BJ, Blair J. Rapidly soluble oral dosage forms, method of making same, and composition thereof. US patent 5762961; 1998.
 14. Bradoo R. Fast Dissolving Drug Delivery Systems. *JAMA India* 2001; 4 (10): 27-31.
 15. Shukla D, Chakraborty S, Singh S, Mishra B. Mouth Dissolving Tablets I: An Overview of Formulation Technology, *Sci Pharm.* 2009; 77: 309-26.
 16. Wilson CG, Washington N, Peach J, Murray GR, Kennerley J. The behavior of a fast dissolving dosage form (Expidet) followed by g-scintigraphy. *Int J Pharm.* 1987; 40: 119-23.
 17. Fix JA. Advances in quick-dissolving tablets technology employing Wowtab. Paper Presented at: IIR Conference on Drug Delivery Systems. 1998 Oct.; Washington DC, USA.
 18. Virely P, Yarwood R. Zydis – a novel, Fast dissolving dosage form. *Manuf Chem.* 1990; 61: 36-37.
 19. Jaccard TT, Leyder J. Une nouvelle forme galenique: le lyoc. [A new galenic form: lyoc]. *Ann Pharm Fr.* 1985; 43: 123-31.
 20. Dong Y, Kulkarni R, Behme R J, Kotiyan PN. Effect of the melt granulation technique on the dissolution characteristics of griseofulvin. *International Journal of Pharmaceutics* 2007; 329 (1, suppl 2): 72-80.
 21. Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier J P, Piccerelle P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. *International Journal of Pharmaceutics* 2004; 278(2): 423-33.
 22. Kuno Y, Kojima M, Ando S, Nakagami H. Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols. *Journal of Controlled Release* 2005; 105(1, suppl 2): 16-22.
 23. Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. *International Journal of Pharmaceutics* 1997; 152(1): 127-31.
 24. Gohel M, Patel M, Amin A, Agrawal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. *AAPS PharmSciTech* 2004; 5(3): 10-15.
 25. Yu DG, Shen XX, Han J, Zhu LM, Branford-White C, Li XY, Yang XL. Oral Fast-Dissolving DDD Fabricated Using 3DP, Bioinformatics and Biomedical Engineering. The 2nd International Conference 2008; 1602-605.
 26. Ito A, Sugihara M. Development of oral dosage forms for elderly patients: use of agar as base of rapidly disintegrating oral tablets. *Chem Pharm. Bull.* 1996; 44(11): 2132-136.
 27. Bhaskaran S, Narmada GV. Rapid dissolving tablets a novel dosage form. *Indian Pharmacist.* 2002; 1: 9-12.
 28. Mishra DN, Bimodal M, Singh SK, Vijaya Kumar SG. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. *Chem Pharm Bull* 2006; 54(1): 99-102.
 29. Myers GL, Battist GE, Fuisz RC. Process and apparatus for making rapidly dissolving dosage units and product there from. PCT Patent WO 95/34293-A1; 1995.
 30. Cherukuri SR, Myers GL, Battist GE, Fuisz RC. Quickly dispersing comestible unit and product. PCT Patent WO 95/34290-A1; 1995.
 31. Cherukuri SR, Myers GL, Battist GE, Fuisz RC. Process for forming quickly dispersing comestible unit and product there from. US Patent 5587172; 1996.
 32. Fuisz R. Ulcer prevention method using a melt-spun hydrogel. US Patent 5622717; 1997.
 33. Fuisz R, Cherukuri SR. Process and apparatus for making tablets and tablets made there from. US Patent 5654003; 1997.
 34. Myers GL, Battist GE, Fuisz RC. Delivery of controlled-release systems. US Patent 5567439; 1996.

35. Myers GL, Battist GE, Fuisz RC. Apparatus for making rapidly dissolving dosage units. US Patent 5871781; 1999.
36. Cherukuri SR, Fuisz R. Process and apparatus for making tablets and tablets made there from. US Patent 5654003; 1997.
37. Myers GL, Battist GE, Fuisz RC. Ulcer prevention method using a melt-spun hydrogel. US Patent 5622719; 1997.
38. Bhowmik D, Chiranjib B, Pankaj K, Chandira RM. Fast Dissolving Tablet: An Overview. *Journal of Chemical and Pharmaceutical Research* 2009; 1(1): 163-77.
39. Elan Corporation, plc. Orally Disintegrating Tablets (ODT) - Nanomelt™. http://www.elan.com/EDT/nanocrystal%5Ftechnology/orally_disintegrating_tablet.asp
40. Mizumoto T, Tamura T, Kawai H, Kajiyama A. Formulation Design of Taste-Masked Particles, Including Famotidine, for an Oral Fast-Disintegrating Dosage Form. *Chem. Pharm. Bull.* 2008; 56(4): 530-35.
41. Sugimoto M, Narisawa S, Matsubara K, Yoshino H. Effect of Formulated Ingredients on Rapidly Disintegrating Oral Tablets Prepared by the Crystalline Transition Method. *Chem. Pharm. Bull.* 2006; 54(2): 175-80.
42. Watanabe Y, Zama Y, Matsumoto M. New compressed tablet rapidly disintegrating in saliva in the mouth using crystalline cellulose and a disintegrants. *Biol. Pharm. Bull.* 1995; 18(9): 1308-10.
43. Mallikarjuna Setty C, Prasad DVK, Gupta VRM. Development of fast dispersible aceclofenac tablets: Effect of functionality of superdisintegrants. *Indian journal of pharmaceutical sciences* 2008; 70(2): 180-85.
44. Patel NV, Chotai NP, Patel MP. Formulation design of oxcarbazepine fast-release tablets prepared by melt granulation technique. *Asian Journal of Pharmaceutics* 2008; 22-25.
45. Sharma S, Gupta GD. Formulation and characterization of fast-dissolving tablet of promethazine theoclate. *Asian Journal of Pharmaceutics* 2008; 70-72.
46. Mohapatra A, Parikh RK, Gohel MC. Formulation, development and evaluation of patient friendly dosage forms of metformin, Part-I: Orally disintegrating tablets. *Asian Journal of Pharmaceutics* 2009; 167-71.
47. Sammour OA, Hammad MA, Megrab NA. Formulation and Optimization of Mouth Dissolve Tablets Containing Rofecoxib Solid Dispersion. *AAPS PharmSciTech.* 2006; 7(2): 162-69.
48. Fini A, Bergamante V, Ceschel GC, Ronchi C. Fast dispersible/slow releasing ibuprofen tablets. *European Journal of Pharmaceutics and Biopharmaceutics* 2008; 69: 335-41.